Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.

Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD.

Br J Haematol. 2007 Nov;139(3):398-404.

PMID:
17910629
2.
3.

The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, Williams DC, Zisterer DM, Lawler M.

Cancer Res. 2009 Nov 1;69(21):8366-75. doi: 10.1158/0008-5472.CAN-09-0131. Epub 2009 Oct 13.

5.

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.

Robak T, Blonski JZ, Gora-Tybor J, Kasznicki M, Konopka L, Ceglarek B, Komarnicki M, Lewandowski K, Hellmann A, Lewandowski K, Moskwa A, Dmoszyńska A, Sokołowska B, Dwilewicz-Trojaczek A, Tomaszewska A, Sułek K, Całbecka M.

Eur J Cancer. 2004 Feb;40(3):383-9.

PMID:
14746857
6.

Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.

Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F.

Blood. 1999 Jul 15;94(2):448-54. Review.

7.

The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.

Parekh K, Rusch V, Kris M.

Cancer. 1999 Nov 1;86(9):1720-3.

PMID:
10547544
8.

Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome.

Robak T, Urbańska-Ryś H, Strzelecka B, Krykowski E, Bartkowiak J, Bĺoński JZ, Kordek R, Warzocha K.

Eur J Haematol. 2001 Nov-Dec;67(5-6):322-7.

PMID:
11872081
9.

Mycosis fungoides associated with B-cell malignancies.

Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E.

Br J Dermatol. 2006 Aug;155(2):379-86.

PMID:
16882178
10.

Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.

García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C.

Am J Hematol. 2005 Dec;80(4):271-81.

11.

Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.

Fong D, Kaiser A, Spizzo G, Gastl G, Tzankov A.

Br J Haematol. 2005 Apr;129(2):199-205.

PMID:
15813847
12.

Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.

Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, Reman O, Vey N, Lhéritier V, Dombret H, Thomas X.

Cancer. 2007 Dec 15;110(12):2747-55.

14.

CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia.

Xu W, Li JY, Wu YJ, Yu H, Shen QD, Tian T, Li L, Qiu HX.

Leuk Res. 2009 Feb;33(2):237-43. doi: 10.1016/j.leukres.2008.06.026. Epub 2008 Jul 31.

PMID:
18674817
15.

Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.

Nemets A, Ben Dor D, Barry T, Ducach A, Blumental R, Ben Alon D, Lugassy G.

Leuk Lymphoma. 2003 Dec;44(12):2151-4.

PMID:
14959863
16.

Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.

Castejón R, Yebra M, Citores MJ, Villarreal M, García-Marco JA, Vargas JA.

Leuk Lymphoma. 2009 Apr;50(4):593-603. doi: 10.1080/10428190902780669.

PMID:
19373658
17.

Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.

Tsang RY, Santos C, Ghosh S, Dabbagh L, King K, Young J, Cass CE, Mackey JR, Lai R.

Mod Pathol. 2008 Nov;21(11):1387-93. doi: 10.1038/modpathol.2008.110. Epub 2008 Jul 4.

18.

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.

Clin Cancer Res. 2008 Jan 1;14(1):155-61. doi: 10.1158/1078-0432.CCR-07-1371.

19.

The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL).

Giannopoulos K, Schmitt M, Kowal M, Własiuk P, Bojarska-Junak A, Roliński J, Dmoszyńska A.

Leuk Res. 2008 Dec;32(12):1815-9. doi: 10.1016/j.leukres.2008.04.008. Epub 2008 May 21.

PMID:
18499249
20.

The prevalence of ocular disease in chronic lymphocytic leukaemia.

Buchan J, McKibbin M, Burton T.

Eye (Lond). 2003 Jan;17(1):27-30.

PMID:
12579166

Supplemental Content

Support Center